Baurzhan Aipov

Dr. Baurzhan Aipov

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
BABaurzhan Aipov
Baurzhan Aipov
KNK Nurlan
K Nurlan
ZAZ Aldanysh
Z Aldanysh
ATA Taukelova
A Taukelova
SJS Jetybayeva
S Jetybayeva
AKAlmagul Kushugulova
Almagul Kushugulova
Background. The objective of this study was to investigate the prevalence of periodontitis in patients with chronic heart failure, as well as to characterize the microbiological profile of periodontitis across different chronic heart failure phenotypes. The objective is to analyze the link between oral health and heart disease. Materials and Methods. A cohort of 98 chronic heart failure patients (mean age 62.22 ± 8.62 years, 69 men) was assessed through comprehensive cardiological and periodontal examinations. Patients were categorized into heart failure with reduced ejection fraction, mildly reduced ejection fraction, and preserved ejection fraction. Periodontal parameters, including probing pocket depth, clinical attachment loss, and bleeding on probing were evaluated. Microbiological and statistical analyses were conducted. Results. Severe periodontitis (Stage C) was identified in 30% of patients, while 48% had moderate periodontitis (Stage B). Patients with chronic heart failure with reduced ejection fraction exhibited the highest prevalence of severe periodontitis, with a significant correlation between increased probing pocket depth and reduced ejection fraction. Candida species abundance was associated with lower ejection fraction (p≤0.0Y) and advanced periodontitis (p≤0.0X). Elevated NT-proBNP levels (1121.00–7611.00 pg/mL) correlated with Streptococcus mitis prevalence, while C-reactive protein levels (up to 2.35 mg/dL) were highest in patients with Klebsiella pneumoniae. Conclusion. The study highlights a strong association between periodontal disease, microbial dysbiosis, and CHF. Findings suggest that oral microbial imbalances, particularly involving Candida, Streptococcus mitis, and Klebsiella pneumoniae, contribute to systemic inflammation and cardiovascular complications.

30 December 2024 in Наука и здравоохранение
Verified
Journal Article
Open access
MBM.S. Bekbosynova
M.S. Bekbosynova
SJS.K. Jetybaeva
S.K. Jetybaeva
BABaurzhan Aipov
Baurzhan Aipov
KNK.R. Nurlan
K.R. Nurlan
ASA.I. Sailybaeva
A.I. Sailybaeva
AKAlmagul Kushugulova
Almagul Kushugulova
Background. Chronic heart failure (CHF) is a global health issue with high mortality rates. According to statistical data, in Kazakhstan, 4.7% of the population suffers from CHF, which amounts to approximately 320,000 people. In the United States, 6.7 million individuals are affected, with projections rising to 8.5 million by 2030. Despite advancements in treatment, mortality rates remain high. Recent studies highlight the role of gut microbiota in systemic inflammation, a key factor in cardiovascular diseases. Exploring the gut microbiota offers a novel perspective for understanding CHF pathogenesis and potential therapeutic interventions. Aim. The review aims to explore the role of gut microbiota in the development and progression of CHF and examine new methods to improve the clinical status of patients through gut microbiota modulation. Search strategy. A literature review was conducted using PubMed, Medline, Cochrane Central register of Controlled Trials database, Web of Science, Scopus, https://elibrary.ru, and Google Scholar over the past 10 years, providing information on the role of the gut microbiota in the development and progression of CHF. The review includes works published in Russian and English Results. Disruption of the intestinal barrier allows endotoxins and microbial metabolites to enter systemic circulation, triggering systemic inflammation and endothelial dysfunction, exacerbating CHF. Gut hypoperfusion and increased permeability further contribute to the disease's progression. Microbial metabolites, such as trimethylamine-N-oxide (TMAO) and short-chain fatty acids (SCFAs), influence systemic inflammation. Elevated TMAO levels are linked to cardiovascular events, while SCFAs have protective effects but are reduced in CHF patients. Gut dysbiosis is prevalent in CHF, marked by altered microbiota composition, including decreased beneficial bacteria and increased pathogenic species. These changes correlate with systemic inflammation and disease severity. Conclusions.The gut microbiota significantly impacts CHF pathogenesis through its influence on systemic inflammation and metabolic pathways. Modulating gut microbiota presents promising therapeutic opportunities, including dietary adjustments, probiotics, prebiotics, and fecal microbiota transplantation. Further research is essential to optimize interventions and explore the gut-heart axis's role in CHF progression and comorbidities. Введение. Хроническая сердечная недостаточность (ХСН) представляет собой глобальную проблему здравоохранения с высокой смертностью. Согласно статистическим данным в Казахстане 4,7 % населения страдает от ХСН, что составляет примерно 320 тыс. чел. В США страдают ХСН 6,7 млн человек, к 2030 году прогнозируется увеличение числа пациентов до 8,5 млн. В целом глобальная распространенность ХСН варьируется от 100 до 900 случаев на 100 тыс. человеко-лет в зависимости от используемых диагностических критериев и исследуемой популяции. Несмотря на достижения в лечении ХСН, сохраняются высокая частота госпитализаций и смертность. Новые исследования уделяют внимание роли кишечной микробиоты в развитии системного воспаления, которое играет важную роль в патогенезе сердечно-сосудистых заболеваний. Изучение микробиоты открывает новые перспективы в понимании патогенеза ХСН и разработке терапевтических подходов. Цель исследования. Исследовать роль кишечной микробиоты в развитии и прогрессировании ХСН, а также рассмотреть новые методы коррекции клинического состояния пациентов путем модуляции микробиоты. Стратегия поиска. Поиск литературы проводился с использованием ресурсов PubMed, Medline, Центрального реестра контролируемых испытаний Cochrane, Web of Science, Scopus, https://elibrary.ru и Google Scholar за последние 10 лет, предоставляющий информацию о роли микробиоты кишечника в развитии и прогрессировании ХСН. Обзор включает работы, опубликованные на русском и английском языках. Результаты. Нарушение барьерной функции кишечника способствует проникновению эндотоксинов и микробных метаболитов в системный кровоток, что вызывает системное воспаление и эндотелиальную дисфункцию, ухудшающую течение ХСН. Гипоперфузия кишечника и увеличение его проницаемости усугубляют прогрессирование заболевания. Метаболиты микробиоты, такие как триметиламин-N-оксид (ТМАО) и короткоцепочечные жирные кислоты (КЦЖК), участвуют в развитии системного воспаления. Высокий...

30 June 2025 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
BMBekbosynova M
Bekbosynova M
AKAlmagul Kushugulova
Almagul Kushugulova
JSJetybayeva S
Jetybayeva S
TSTaukelova S
Taukelova S
MAMyrzakhmetova A
Myrzakhmetova A
TSTleubaeva S
Tleubaeva S
Background. With the aging population, the number of people with frailty syndromes receiving treatment for cardiovascular diseases is increasing. Diagnosis of frailty syndrome prior to complex and invasive procedures may have implications for prognosis and recovery. The aim of this study was to assess the prevalence of frailty and describe its associated clinical course and outcomes in patients referred for cardiac surgery. Materials and methods. A prospective cohort of patients over 18 years of age referred for cardiac surgery at the non-profit joint-stock company "National Scientific Cardiac Surgery Center" in Astana, Department of Cardiac Surgery, from November 2022 to April 2023, was examined before surgery for the presence of frailty, determined by the deficit accumulation model scale. The analysis included clinical, anamnestic, instrumental and laboratory data, surgical results, development of complications and adverse outcomes in the perioperative period. Statistical processing of the study results was performed. Results. Fragility was detected in 32% of patients before open cardiac surgery. Differences were revealed in the intraoperative and early postoperative periods: rhythm disturbances developed more often (20.8% versus 3.9%), transient ischemic attack / acute cerebrovascular accident of the ischemic type (8.3% versus 3.9%), hydrothorax (31.25% versus 11.7% and 5.8%), implantation of extracorporeal membrane oxygenation (12.5 % versus 3.9%) .In the group of patients with frailty, two fatal outcomes were recorded. Conclusions. Frailty was observed in 32% of patients undergoing cardiac surgery and was associated with higher risk of morbidity and increased healthcare utilization.

Verified
Journal Article
Open access
PDF file
RARassulbek Aipov
Rassulbek Aipov
TSTimur Saliev
Timur Saliev
BABaurzhan Aipov
Baurzhan Aipov
ZKZulfiya Kachiyeva
Zulfiya Kachiyeva
AOAksoltan Oradova
Aksoltan Oradova
IFIldar Fakhradiyev
Ildar Fakhradiyev
Atherosclerosis remains a leading global cause of cardiovascular morbidity and mortality, yet its insidious progression and multifaceted etiology, spanning genetic, metabolic, and environmental determinants, often delay clinical recognition until adverse events occur. Traditional risk stratification tools, while foundational in preventive cardiology, are constrained by their reliance on limited variables and static linear assumptions, frequently misclassifying individuals at the extremes of risk. This review critically examines the transformative role of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), in redefining atherosclerosis management across three interconnected domains. First, we explore how AI-driven predictive models integrate high-dimensional data, from genomics and imaging to real-time wearable metrics, to achieve superior cardiovascular risk stratification compared with conventional scores. Second, we detail AI’s capacity to automate and enhance plaque characterization through advanced imaging analysis, enabling reproducible quantification of burden, composition, and vulnerability markers that are imperceptible to human readers. Third, we investigate AI-powered clinical decision support systems, digital twins, and reinforcement learning approaches that facilitate dynamic, personalized treatment planning tailored to each patient’s evolving profile. We also critically address the ethical imperatives, algorithmic fairness, data privacy, transparency, and accountability, alongside practical challenges of clinical integration, regulatory validation, and health equity.